Summary of clinical courses with FLT3-ITD allelic ratio, ME ratio, and % blasts of bone marrow. ME ratio strikingly decreased by numerous erythroid precursors identified after initiation of gilteritinib treatment, whereas blasts significantly decreased. FLT3-ITD allelic ratio increased following gilteritinib treatment. Both FLT3-ITD and blasts became undetectable at day 30 after HCT.